lol646 m ph

lol646 m ph Pramod Kumar Voola has emerged as a key leader in healthcare IT, with a remarkable career focused on revolutionizing clinical trials and advocating for ethical AI practices. With expertise in data engineering, test automation, and AI, Pramod has made significant strides in improving patient safety and streamlining clinical processes. His work in data streaming for GenAI applications and mobile automation in clinical trials is reshaping the landscape of healthcare technology. In his role, Pramod has closely worked with electronic Clinical Outcome Assessments (eCOA) platforms, which are critical in ensuring data accuracy and patient safety during clinical trials. He emphasizes the importance of technology in eliminating human errors and enhancing data collection. "With eCOA, we ensure that patient-reported outcomes are captured precisely, reducing errors and improving data quality," Pramod explains. The use of real-time monitoring in clinical trials, enabled by advanced technology, also allows early detection of risks, reducing the likelihood of adverse outcomes. Leading cross-functional teams across multiple domains is another area where Pramod excels. He highlights the importance of empathy, communication, and insight management in effective leadership. By fostering collaboration among diverse teams, he ensures that every team member contributes their expertise to achieve shared goals. “Cross-functional management is about managing insights, not just outputs,” he notes, underscoring the importance of a collaborative spirit in delivering successful projects. Pramod is also a passionate advocate for the ethical use of artificial intelligence in healthcare. He believes that AI, especially in the sensitive field of clinical trials, must be designed with responsibility and respect for patients' rights. “Ethical AI is about eliminating biases in algorithms and ensuring that all patients are treated equally,” he explains. Pramod’s dedication to this cause is reflected in his active participation in Ethical AI groups, where he works to ensure that AI systems are built with both innovation and humanity in mind. Mobile automation is another key focus area in Pramod’s work. He has led initiatives to integrate mobile technology into clinical trials, which has significantly transformed how data is collected and managed. Mobile apps now allow patients to participate in trials remotely, making the process more accessible and reducing the need for manual testing. “Mobile automation has sped up clinical trials, improved data quality, and made patient engagement more efficient,” he says, highlighting the impact of technology on trial outcomes. Looking ahead, Pramod is excited about the future of AI in healthcare, particularly the potential of predictive analytics and personalized treatment. He envisions a future where AI helps create more inclusive clinical trials and accelerates the development of new treatments. “AI and data science will not just optimize trial outcomes; they will help tailor treatments to individual patients,” he concludes. Pramod Kumar Voola’s work is not only advancing the technological frontiers of healthcare but also ensuring that these innovations are used ethically and responsibly, making a lasting impact on patient care and clinical outcomes.

Xiaomi’s new campaign shows Redmi Note 14 5G series' durability through a CGI-enabled billboard

As Alibaba continues to expand its cloud computing operations and serve a growing number of customers globally, incidents like the recent fire underscore the need for continuous vigilance and proactive measures to mitigate risks and ensure the uninterrupted delivery of cloud services.Chuck Woolery Dies: Former ‘Wheel of Fortune’ and ‘Love Connection’ Host Was 83

KBC Group NV purchased a new position in shares of American Healthcare REIT, Inc. ( NYSE:AHR – Free Report ) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,967 shares of the company’s stock, valued at approximately $51,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of AHR. Kozak & Associates Inc. purchased a new stake in shares of American Healthcare REIT in the third quarter valued at approximately $28,000. Kiely Wealth Advisory Group Inc. purchased a new stake in American Healthcare REIT in the 2nd quarter valued at $30,000. Amalgamated Bank purchased a new stake in American Healthcare REIT in the 2nd quarter valued at $33,000. Semmax Financial Advisors Inc. acquired a new stake in shares of American Healthcare REIT in the 2nd quarter worth $45,000. Finally, Kessler Investment Group LLC purchased a new position in shares of American Healthcare REIT during the 3rd quarter worth $48,000. 16.68% of the stock is currently owned by institutional investors and hedge funds. American Healthcare REIT Trading Up 0.8 % AHR opened at $28.58 on Friday. The company has a quick ratio of 0.37, a current ratio of 0.37 and a debt-to-equity ratio of 0.59. The firm has a market cap of $4.37 billion and a P/E ratio of -59.54. American Healthcare REIT, Inc. has a 52 week low of $12.63 and a 52 week high of $28.68. The business has a fifty day simple moving average of $25.82 and a 200-day simple moving average of $19.84. American Healthcare REIT Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, September 20th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend was Friday, September 20th. American Healthcare REIT’s payout ratio is currently -208.33%. Wall Street Analysts Forecast Growth AHR has been the subject of a number of analyst reports. JMP Securities upped their price objective on shares of American Healthcare REIT from $18.00 to $30.00 and gave the company a “market outperform” rating in a report on Friday, September 20th. Royal Bank of Canada increased their price target on shares of American Healthcare REIT from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Bank of America lifted their price target on shares of American Healthcare REIT from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Colliers Securities upgraded American Healthcare REIT from a “hold” rating to a “moderate buy” rating in a research report on Sunday, October 13th. Finally, Morgan Stanley raised their target price on American Healthcare REIT from $17.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.13. Get Our Latest Research Report on AHR American Healthcare REIT Company Profile ( Free Report ) Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value. Read More Five stocks we like better than American Healthcare REIT How to Buy Cheap Stocks Step by Step Vertiv’s Cool Tech Makes Its Stock Red-Hot Health Care Stocks Explained: Why You Might Want to Invest MarketBeat Week in Review – 11/18 – 11/22 3 Fintech Stocks With Good 2021 Prospects 2 Finance Stocks With Competitive Advantages You Can’t Ignore Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. ( NYSE:AHR – Free Report ). Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter .In a groundbreaking move for the Chinese film and television industry, the inaugural AIGC Director Co-creation Program University Roadshow has been officially launched. The program, initiated by the AI Graph Cinema (AIGC) Technology Co., Ltd., aims to revolutionize the creative process in the entertainment sector by leveraging cutting-edge artificial intelligence technology. At the heart of this initiative is the introduction of "KeLing AI," an innovative tool that is set to reshape the landscape of film and television production.

Labor eyes last chance of 2024 to tick policy boxes

Nigerian Govt saved $20bn by removing subsidies – Finance minister, EdunKBC Group NV bought a new stake in Cassava Sciences, Inc. ( NASDAQ:SAVA – Free Report ) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,944 shares of the company’s stock, valued at approximately $57,000. A number of other institutional investors and hedge funds have also modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in Cassava Sciences in the 3rd quarter valued at about $10,610,000. State Board of Administration of Florida Retirement System lifted its position in shares of Cassava Sciences by 5.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,149 shares of the company’s stock valued at $247,000 after acquiring an additional 650 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Cassava Sciences by 146.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after acquiring an additional 5,594 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Cassava Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company’s stock worth $47,813,000 after purchasing an additional 31,854 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Cassava Sciences by 18.1% during the second quarter. Bank of New York Mellon Corp now owns 140,847 shares of the company’s stock worth $1,739,000 after purchasing an additional 21,558 shares in the last quarter. Hedge funds and other institutional investors own 38.05% of the company’s stock. Wall Street Analysts Forecast Growth Several brokerages have issued reports on SAVA. Rodman & Renshaw reaffirmed a “buy” rating and set a $107.00 target price on shares of Cassava Sciences in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $116.00 price target on shares of Cassava Sciences in a research report on Friday, November 8th. Cassava Sciences Price Performance SAVA stock opened at $26.48 on Friday. Cassava Sciences, Inc. has a 1 year low of $8.79 and a 1 year high of $42.20. The firm has a market capitalization of $1.27 billion, a PE ratio of -19.19 and a beta of -0.59. The business has a 50 day simple moving average of $27.55 and a 200-day simple moving average of $23.38. Cassava Sciences ( NASDAQ:SAVA – Get Free Report ) last issued its earnings results on Thursday, November 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.79. During the same period in the previous year, the firm earned ($0.61) earnings per share. On average, equities research analysts expect that Cassava Sciences, Inc. will post -3.63 EPS for the current year. Cassava Sciences Profile ( Free Report ) Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. See Also Five stocks we like better than Cassava Sciences The Most Important Warren Buffett Stock for Investors: His Own Vertiv’s Cool Tech Makes Its Stock Red-Hot EV Stocks and How to Profit from Them MarketBeat Week in Review – 11/18 – 11/22 What is the FTSE 100 index? 2 Finance Stocks With Competitive Advantages You Can’t Ignore Want to see what other hedge funds are holding SAVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cassava Sciences, Inc. ( NASDAQ:SAVA – Free Report ). Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter .

Wright believes that Ramsdale's potential arrival at Stamford Bridge would not only strengthen Chelsea's defense but also provide healthy competition for current goalkeeper Edouard Mendy. The competition for the number one spot would push both goalkeepers to elevate their performances and maintain a high level of consistency, ultimately benefiting the team as a whole.Amorim vows to hold on despite Rashford row

HUAWEI Launches Groundbreaking Products to Redefine Foldable, Audio, and Design ExcellenceChristmas presents donated by the people in the were distributed to young children in state hospitals on Tuesday. The presents were collected around a Christmas tree on Castille Square in the past few days. The prime minister and his wife Lydia Abela were among those who distributed them on Christmas Eve at Mater Dei Hospital and Sir Anthony Mamo Oncology Centre. They were accompanied by Health Minister Jo Etienne Abela. The prime minister also met the directors of Puttinu Cares and thanked them for their work for sick children. He promised them the country's support. You can unsubscribe at any time by clicking the link in the footer of our emails. We use as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.

Replacing McConnell? Someone reserves Senate 2026 web domains for 6 prominent KentuckiansCurling Canada unveils 16 mixed doubles teams vying to wear Maple Leaf in 2026

Waterdrop Credit, a leading provider of credit monitoring and identity protection services, suggested that the man should contact the relevant companies directly to rectify the situation. According to the man, the text messages he received were from various financial institutions and credit bureaus, alerting him about changes to his credit report and credit score. While he acknowledged that he had not initiated any of these activities himself, he was worried about the potential implications on his financial reputation and creditworthiness.

SEATTLE (AP) — The Seattle Seahawks took a bumpy path to sole possession of first place in the NFC West. Sunday’s 26-21 win over the Jets featured several special teams miscues, including a 99-yard kickoff return for a touchdown by New York. On the flip side, the Seahawks got their second pick-6 in as many weeks and just enough production by Geno Smith and the offense. The Seahawks’ uneven performance was characteristic of a season in which they started 3-0, then lost five of six before winning another three in a row to take command of their underachieving division. Seattle (7-5) leads Arizona by one game, with a matchup against the Cardinals looming next weekend. Zach Charbonnet gave Seattle its first lead of the day on an 8-yard touchdown run with 5:37 to go, and the Seahawks’ defense capped another strong outing with a game-sealing stop on fourth down. After a sack by Leonard Williams gave the Jets a fourth-and-15 at the 34-yard line, Aaron Rodgers threw a desperation pass to Garrett Wilson that fell incomplete, giving Seattle the ball with 33 seconds left. RELATED COVERAGE 49ers are nearing rock bottom following a blowout loss and the injury to McCaffrey Jim Harbaugh’s Chargers are in good position for the playoffs but need to improve on offense The Vikings are showing their worth at 10-2 by winning the games that don’t go smoothly What’s working Williams is on a tear. After losing out on NFC defensive player of the week honors last week to teammate Coby Bryant despite 2 1/2 sacks and four quarterback hits, “Big Cat” had an even better game. Williams finished with two sacks, three tackles for loss, a 92-yard interception return for a touchdown that was the longest pick-6 in NFL history by a defensive lineman, and a blocked extra point. The touchdown was the first of Williams’ career. He became the first player since 1982 with multiple sacks, an interception return for a touchdown and a blocked kick in a game. Maybe this week the league will agree he was the NFC’s best defender. The AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . What needs help The special teams could not have been much worse in the first half. The Seahawks fumbled three kickoffs, losing two, and allowed Kene Nwangwu’s 99-yard kickoff return for a TD. Dee Williams fumbled on a kickoff in the first quarter to give New York the ball at the 27-yard line, and four plays later, Rodgers hit Isaiah Davis for a touchdown to give the Jets a 14-0 lead. Laviska Shenault Jr. muffed two kicks and fumbled at the Seattle 38-yard line in the second quarter. Seattle also had an extra point blocked. Stock up Smith led his third game-winning drive of the season and his 11th since he became Seattle’s starting quarterback in 2022. Facing the team that drafted him in 2013, Smith went 20 of 31 for 206 yards and a touchdown. For the first time in five weeks, he was not intercepted. The Seahawks trailed by 14 points on two occasions, but Smith brought Seattle back while avoiding the untimely picks that dogged him recently. He threw a 12-yard touchdown pass to A.J. Barner in the second quarter, and led the Seahawks on a go-ahead nine-play, 71-yard touchdown drive late in the fourth quarter. Stock down Coach Mike Macdonald and his staff have to address the problem with their kick returners, Shenault and Dee Williams. Two lost fumbles and several muffs could have easily cost Seattle the game. Injuries WR DK Metcalf left the game briefly with a knee issue but returned. ... P Michael Dickson was unavailable in the fourth quarter because of back spasms. Key number 38 — The Seahawks decided to go for it on fourth-and-6 at their own 33-yard line with 9:34 left in the game. A primary reason was that Dickson was unavailable to punt because of back spasms. The Jets were flagged for having 12 men on the field after sending a punt returner out, which gave Seattle fourth-and-1 at the 38. The Seahawks got a first down after Jets cornerback Quantez Stiggers was flagged for pass interference on Metcalf, and eight players later, Charbonnet scored to put Seattle ahead. Without going for it on fourth down from their own 38, the Seahawks likely would’ve lost. Up next The Seahawks will seek a season sweep of the Cardinals. ___ AP NFL: https://apnews.com/hub/nfl

Low rates of flu vaccine take-up: Concerns for the season ahead